Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Septicemia | Research

Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration

Authors: Benjamin Gershkovich, Shannon M. Fernando, Brent Herritt, Lana A. Castellucci, Bram Rochwerg, Laveena Munshi, Sangeeta Mehta, Andrew J. E. Seely, Daniel I. McIsaac, Alexandre Tran, Peter M. Reardon, Peter Tanuseputro, Kwadwo Kyeremanteng

Published in: Critical Care | Issue 1/2019

Login to get access

Abstract

Background

Patients with hematologic malignancies who are admitted to hospital are at increased risk of deterioration and death. Rapid response systems (RRSs) respond to hospitalized patients who clinically deteriorate. We sought to describe the characteristics and outcomes of hematologic oncology inpatients requiring rapid response system (RRS) activation, and to determine the prognostic accuracy of the SIRS and qSOFA criteria for in-hospital mortality of hematologic oncology patients with suspected infection.

Methods

We used registry data from two hospitals within The Ottawa Hospital network, between 2012 and 2016. Consecutive hematologic oncology inpatients who experienced activation of the RRS were included in the study. Data was gathered at the time of RRS activation and assessment. The primary outcome was in-hospital mortality. Logistical regression was used to evaluate for predictors of in-hospital mortality.

Results

We included 401 patients during the study period. In-hospital mortality for all included patients was 41.9% (168 patients), and 145 patients (45%) were admitted to ICU following RRS activation. Among patients with suspected infection at the time of RRS activation, Systemic Inflammatory Response Syndrome (SIRS) criteria had a sensitivity of 86.9% (95% CI 80.9–91.6) and a specificity of 38.2% (95% CI 31.9–44.8) for predicting in-hospital mortality, while Quick Sequential Organ Failure Assessment (qSOFA) criteria had a sensitivity of 61.9% (95% CI 54.1–69.3) and a specificity of 91.4% (95% CI 87.1–94.7). Factors associated with increased in-hospital mortality included transfer to ICU after RRS activation (adjusted odds ratio [OR] 3.56, 95% CI 2.12–5.97) and a higher number of RRS activations (OR 2.45, 95% CI 1.63–3.69). Factors associated with improved survival included active malignancy treatment at the time of RRS activation (OR 0.54, 95% CI 0.34–0.86) and longer hospital length of stay (OR 0.78, 95% CI 0.70–0.87).

Conclusions

Hematologic oncology inpatients requiring RRS activation have high rates of subsequent ICU admission and mortality. ICU admission and higher number of RRS activations are associated with increased risk of death, while active cancer treatment and longer hospital stay are associated with lower risk of mortality. Clinicians should consider these factors in risk-stratifying these patients during RRS assessment.
Appendix
Available only for authorised users
Literature
1.
Yeo CD, Kim JW, Kim SC, Kim YK, Kim KH, Kim HJ, et al. Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. J Crit Care. 2012;27(6):739.e1–6.
2.
Guven GS, Uzun O, Cakir B, Akova M, Unal S. Infectious complications in patients with hematological malignancies consulted by the infectious diseases team: a retrospective cohort study (1997-2001). Support Care Cancer. 2006;14(1):52–5.PubMed
3.
Franchini M, Frattini F, Crestani S, Bonfanti C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013;39(1):94–100.PubMed
4.
Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18.PubMed
5.
6.
Jones DA, DeVita MA, Bellomo R. Rapid-response teams. N Engl J Med. 2011;365(2):139–46.PubMed
7.
Chan PS, Khalid A, Longmore LS, Berg RA, Kosiborod M, Spertus JA. Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA. 2008;300(21):2506–13.PubMed
8.
Jacques T, Harrison GA, McLaws ML. Attitudes towards and evaluation of medical emergency teams: a survey of trainees in intensive care medicine. Anaesth Intensive Care. 2008;36(1):90–5.PubMed
9.
Chan PS, Jain R, Nallmothu BK, Berg RA, Sasson C. Rapid response teams: a systematic review and meta-analysis. Arch Intern Med. 2010;170(1):18–26.PubMed
10.
Winters BD, Weaver SJ, Pfoh ER, Yang T, Pham JC, Dy SM. Rapid-response systems as a patient safety strategy: a systematic review. Ann Intern Med. 2013;158(5 Pt 2):417–25.PubMedPubMedCentral
11.
Maharaj R, Raffaele I, Wendon J. Rapid response systems: a systematic review and meta-analysis. Crit Care. 2015;19:254.PubMedPubMedCentral
12.
Jones D, Bellomo R, Bates S, Warrillow S, Goldsmith D, Hart G, et al. Long term effect of a medical emergency team on cardiac arrests in a teaching hospital. Crit Care. 2005;9(6):R808–15.PubMedPubMedCentral
13.
De Jong A, Jung B, Daurat A, Chanques G, Mahul M, Monnin M, et al. Effect of rapid response systems on hospital mortality: a systematic review and meta-analysis. Intensive Care Med. 2016;42(4):615–7.PubMed
14.
Harrison DA, Gao H, Welch CA, Rowan KM. The effects of critical care outreach services before and after critical care: a matched-cohort analysis. J Crit Care. 2010;25(2):196–204.PubMed
15.
Jones D, Moran J, Winters B, Welch J. The rapid response system and end-of-life care. Curr Opin Crit Care. 2013;19(6):616–23.PubMed
16.
Ball C, Kirkby M, Williams S. Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study. BMJ. 2003;327(7422):1014.PubMedPubMedCentral
17.
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer. 2004;100(2):228–37.PubMed
18.
Burutaran MB, Guadagna R, Grille S, Stevenazzi M, Guillermo C, Diaz L, et al. Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay. Rev Bras Hematol Hemoter. 2015;37(1):28–33.
19.
Engelhart S, Glasmacher A, Exner M, Kramer MH. Surveillance for nosocomial infections and fever of unknown origin among adult hematology-oncology patients. Infect Control Hosp Epidemiol. 2002;23(5):244–8.PubMed
20.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. CHEST. 1992;101(6):1644–55.PubMed
21.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentral
22.
Fernando SM, Reardon PM, Rochwerg B, Shapiro NI, Yealy DM, Seely AJE, et al. Sepsis-3 septic shock criteria and associated mortality among infected hospitalized patients assessed by a rapid response team. Chest. 2018;154(2):309–16.PubMed
23.
Finkelsztein EJ, Jones DS, Ma KC, Pabón MA, Delgado T, Nakahira K, et al. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit Care. 2017;21(1):73.PubMedPubMedCentral
24.
Soubani AO, Kseibi E, Bander JJ, Klein JL, Khanchandani G, Ahmed HP, et al. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest. 2004;126(5):1604–11.PubMed
25.
Pène F, Aubron C, Azoulay E, Blot F, Thiéry G, Raynard B, et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol. 2006;24(4):643–9.PubMed
26.
Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108(3):452–9.PubMed
27.
Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique study. J Clin Oncol. 2013;31(22):2810–8.PubMed
28.
Parakh S, Piggin A, Neeman T, Mitchell I, Crispin P, Davis A. Outcomes of haematology/oncology patients admitted to intensive care unit at the Canberra hospital. Intern Med J. 2014;44(11):1087–94.PubMed
29.
30.
Taheri L, Anandanadesan R, de Lavallade H, Pagkalidou E, Pagliuca A, Mufti G, et al. The role of a critical care outreach service in the management of patients with haematological malignancy. J Intensive Care Soc. 2019;10:1751143719855201.
31.
Azoulay E, Pène F, Darmon M, Lengliné E, Benoit D, Soares M, et al. Managing critically ill hematology patients: time to think differently. Blood Rev. 2015;29(6):359–67.PubMed
32.
Lengliné E, Raffoux E, Lemiale V, Darmon M, Canet E, Boissel N, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. 2012;53(7):1352–9.PubMed
33.
Song J-U, Suh GY, Park HY, Lim SY, Han SG, Kang YR, et al. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012;38(9):1505–13.PubMed
34.
Bokhari SWI, Munir T, Memon S, Byrne JL, Russell NH, Beed M. Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. Ann Hematol. 2010;89(5):505–12.PubMed
35.
Hayani O, Al-Beihany A, Zarychanski R, Chou A, Kharaba A, Baxter A, et al. Impact of critical care outreach on hematopoietic stem cell transplant recipients: a cohort study. Bone Marrow Transplant. 2011;46(8):1138–44.PubMed
36.
Kim W-Y, Hong S-B, Chang YJ, Park T, Seo H, Choi SH, et al. Medical emergency team, changing survival in patients with hemato-oncologic malignancies. Intensive Care Med. 2010;36:S165.
37.
Fernando SM, Reardon PM, McIsaac DI, Eagles D, Murphy K, Tanuseputro P, et al. Outcomes of older hospitalized patients requiring rapid response team activation for acute deterioration. Crit Care Med. 2018;46(12):1953–60.PubMed
38.
Baxter AD, Cardinal P, Hooper J, Patel R. Medical emergency teams at the Ottawa Hospital: the first two years. Can J Anaesth. 2008;55(4):223–31.PubMed
39.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.PubMed
40.
41.
Austin CA, Hanzaker C, Stafford R, Mayer C, Culp L, Lin F-C, et al. Utilization of rapid response resources and outcomes in a comprehensive cancer center*. Crit Care Med. 2014;42(4):905–9.PubMed
42.
Barocas DA, Kulahalli CS, Ehrenfeld JM, Kapu AN, Penson DF, You CC, et al. Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. J Am Coll Surg. 2014;218(1):66–72.PubMed
43.
Fernando SM, Reardon PM, Bagshaw SM, Scales DC, Murphy K, Shen J, et al. Impact of nighttime rapid response team activation on outcomes of hospitalized patients with acute deterioration. Crit Care. 2018;22(1):67.PubMedPubMedCentral
44.
Cornish M, Butler MB, Green RS. Predictors of poor outcomes in critically ill adults with hematologic malignancy. Can Respir J. 2016;2016:9431385.PubMedPubMedCentral
45.
Cassel JB, Jones AB, Meier DE, Smith TJ, Spragens LH, Weissman D. Hospital mortality rates: how is palliative care taken into account? J Pain Symptom Manag. 2010;40(6):914–25.
46.
Jacobson D, Chiu N, Cheung MC, Fowler R, Buckstein R. Predictors for ICU admission and clinical outcomes of malignant hematology patients admitted to critical care units. Blood. 2016;128(22):3595.
47.
Fernando SM, Reardon PM, Scales DC, Murphy K, Tanuseputro P, Heyland DK, et al. Prevalence, risk factors, and clinical consequences of recurrent activation of a rapid response team: a multicenter observational study. J Intensive Care Med. 2018;1:885066618773735.
48.
Stelfox HT, Bagshaw SM, Gao S. Characteristics and outcomes for hospitalized patients with recurrent clinical deterioration and repeat medical emergency team activation*. Crit Care Med. 2014;42(7):1601–9.PubMed
49.
Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29(4):618–26.PubMed
50.
Pastores SM, Goldman DA, Shaz DJ, Kostelecky N, Daley RJ, Peterson TJ, et al. Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer. 2018;124(14):3025–36.PubMedPubMedCentral
51.
de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock. 2013;39(3):250.PubMed
52.
McCaughan D, Roman E, Smith AG, Garry A, Johnson M, Patmore R, et al. Determinants of hospital death in haematological cancers: findings from a qualitative study. BMJ Support Palliat Care. 2018;8(1):78–86.PubMed
53.
Fernando SM, Tran A, Taljaard M, Cheng W, Rochwerg B, Seely AJE, et al. Prognostic accuracy of the quick Sequential Organ Failure assessment for mortality in patients with suspected infection: a systematic review and meta-analysis. Ann Intern Med. 2018;168(4):266–75.PubMed
54.
Driessen RGH, van de Poll MCG, Mol MF, van Mook WNKA, Schnabel RM. The influence of a change in septic shock definitions on intensive care epidemiology and outcome: comparison of sepsis-2 and sepsis-3 definitions. Infectious Dis. 2018;50(3):207–13.
55.
Metadata
Title
Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration
Authors
Benjamin Gershkovich
Shannon M. Fernando
Brent Herritt
Lana A. Castellucci
Bram Rochwerg
Laveena Munshi
Sangeeta Mehta
Andrew J. E. Seely
Daniel I. McIsaac
Alexandre Tran
Peter M. Reardon
Peter Tanuseputro
Kwadwo Kyeremanteng
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2568-5

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue

Research

A prospective investigation of interleukin-8 levels in pediatric acute respiratory failure and acute respiratory distress syndrome

Research

Effects of sedatives and opioids on trigger and cycling asynchronies throughout mechanical ventilation: an observational study in a large dataset from critically ill patients

Research

Death after awakening from post-anoxic coma: the “Best CPC” project

Research

Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care

Research

Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy

Research

The ELSO Maastricht Treaty for ECLS Nomenclature: abbreviations for cannulation configuration in extracorporeal life support - a position paper of the Extracorporeal Life Support Organization